Physician profile
Vannarith So
NPI 1659416584
$532.75
in general payments reported to CMS, 2019-2025
14 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $27.76 · 2021: $34.07 · 2022: $87.86 · 2023: $73.91 · 2024: $38.37 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $118.96 | 2022-2025 | Ingrezza |
| Ucb, INC. | $96.37 | 2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $54.10 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $47.28 | 2019 | |
| Novo Nordisk INC | $36.41 | 2019-2022 | |
| Astellas Pharma US INC | $31.08 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $22.38 | 2021 | |
| Mylan Specialty L.P. | $22.18 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $22.02 | 2024 | Rexulti |
| Urovant Sciences INC | $19.97 | 2022 | |
| Acadia Pharmaceuticals INC | $18.94 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.77 | 2020 | |
| Lundbeck LLC | $13.59 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vannarith So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.